← Back to Screener
Filana Therapeutics, Inc. Common Stock (FLNA)
Price$1.49
Value ScoreB
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (4W)-2.99%
VGM Score84.28
Market Capitalization$74.39M
All Metrics
Book Value / Share (Quarterly)$1.41
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.63
Price vs S&P 500 (YTD)-38.17%
Net Profit Margin (TTM)76.73%
EPS (TTM)$-1.61
10-Day Avg Trading Volume0.40M
EPS Excl Extra (TTM)$-1.61
EPS (Annual)$-1.88
ROI (Annual)-122.27%
Net Profit Margin (5Y Avg)-13.22%
Cash / Share (Quarterly)$1.79
ROA (Last FY)-76.86%
EBITD / Share (TTM)$-1.68
ROE (5Y Avg)-51.20%
Operating Margin (TTM)76.26%
Cash Flow / Share (Annual)$-0.68
P/B Ratio1.09x
P/B Ratio (Quarterly)1.20x
Net Income / Employee (Annual)$-5,351,400
ROA (TTM)-63.35%
EPS Incl Extra (Annual)$-1.88
Current Ratio (Annual)2.23x
Quick Ratio (Quarterly)2.17x
3-Month Avg Trading Volume0.42M
Revenue / Employee (TTM)$0
P/S Ratio (Annual)1.81x
Asset Turnover (Annual)0.82x
52-Week High$2.27
Operating Margin (5Y Avg)-20.88%
EPS Excl Extra (Annual)$-1.88
Quick Ratio (Annual)2.18x
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.19x
Enterprise Value$-12.18M
Asset Turnover (TTM)0.78x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)76.53%
Cash / Share (Annual)$1.98
Net Income / Employee (TTM)$-4,582,400
ROE (Last FY)-122.27%
EPS Basic Excl Extra (Annual)$-1.88
P/FCF (TTM)10.19x
Receivables Turnover (TTM)3.24x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.61
ROI (TTM)-99.85%
P/S Ratio (TTM)1.81x
Pretax Margin (5Y Avg)-14.72%
Revenue / Share (Annual)$0.00
Year-to-Date Return-26.32%
5-Day Price Return17.56%
EPS Normalized (Annual)$-1.88
ROA (5Y Avg)-40.20%
Net Profit Margin (Annual)76.70%
Month-to-Date Return6.21%
EBITD / Share (Annual)$-1.96
Operating Margin (Annual)76.29%
ROI (5Y Avg)-51.20%
EPS Basic Excl Extra (TTM)$-1.61
Pretax Margin (TTM)76.53%
Net Margin Growth (5Y)26.06%
Beta1.18x
P/FCF (Annual)6.64x
Revenue / Share (TTM)$0.00
ROE (TTM)-99.85%
52-Week Low$1.16
vGradeB
mGradeA
vgmGradeA
Show chart for
Analyst Recommendations
Dec 2025
Jan 2026
Feb 2026
Mar 2026
4.00
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
FLNAFilana Therapeutics, Inc. Common Stock | B | — | A | $1.49 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.